However, it should be emphasized that combinations of vemurafenib with other anti-cancer molecules were tested mostly in preclinical models and the only therapeutic combination that was tested clinically is the dual inhibition of BRAF (dabrafenib) and MEK (trametinib), which was evaluated in a phase 2 enrolling 16 BRAF V600E-mutated anaplastic thyroid carcinomas [40]. Here, MAP2K7 is linked to thyroid gland undifferentiated (anaplastic) carcinoma.